Alpha-1-antitrypsin (AAT) deficiency (AATD) is a genetic disease, caused by mutation of the AAT gene. Accumulation of mutated AAT protein aggregates in hepatocytes leads to endoplasmic reticulum stress, resulting in impairment of liver functions and, in some cases, hepatocellular carcinoma, whereas decline of AAT levels in sera is responsible for pulmonary emphysema. In advanced liver disease, the only option for treatment is liver transplantation, whereas AAT replacement therapy is therapeutic for emphysema. Given that hepatocytes are the primary affected cells in AATD, we investigated whether transplantation of bone marrow (BM)-derived stem cells in transgenic mice expressing human AATZ (the Z variant of AAT) confers any competitive advantages compared to host cells that could lead to pathological improvement. Mouse BM progenitors and human mesenchymal stem cells (MSCs) appeared to contribute in replacement of 40% and 13% host hepatocytes, respectively. Transplantation of cells resulted in decline of globule-containing hepatocytes, improvement in proliferation of globuledevoid hepatocytes from the host-derived hepatocytes, and apparently, donor-derived cells. Further analyses revealed that transplantation partially improves liver pathology as reflected by inflammatory response, fibrosis, and apoptotic death of hepatocytes. Cell therapy was also found to improve liver glycogen storage and sera glucose level in mice expressing human AATZ mice. These overall improvements in liver pathology were not restricted to transplantation of mouse BM cells. Preliminary results also showed that following transplantation of human BM-derived MSCs, globule-containing hepatocytes declined and donorderived cells expressed human AAT protein. Conclusion: These results suggest that BM stem cell transplantation may be a promising therapy for AATD-related liver disease. (HEPATOLOGY 2017;65:1319-1335.
A lpha-1-antitrypsin (AAT), the major serine protease inhibitor in serum, is mainly synthesized and secreted by hepatocytes. The physiological function of AAT has been recognized to protect the lungs from proteolytic damage by neutrophil elastase.
(1) AAT deficiency is inherited in an autosomal-codominant pattern. (2) The homozygote for ZZ allele (PiZ) encodes a mutant AAT protein (glu342lys) with altered protein folding, causing protein aggregation in the endoplasmic reticulum (ER) of Abbreviations: AAT, a1-antitrypsin; AATD, a1-antitrypsin deficiency; aHpSCs, activated hepatic stellate cells; Alb, albumin; ATF4, activating transcription factor 4; BM, bone marrow; bp, base pairs; BrdU, bromodeoxyuridine; CHOP, C/-EBP homologous protein; CK, cytokeratin; CPA, collagen proportionate area; CYP2B6, cytochrome P450 2B6; DAPI, 4 0 ,6-diamidino-2-phenylindole; eGFP, enhanced green fluorescence protein; ELISA, enzyme-linked immunosorbent assay; ER, endoplasmic reticulum; FISH, fluorescent in situ hybridization; GADD34, growth arrest and DNAdamage-inducible protein; gDNA, genomic DNA; GRP78/94, glucose-regulated protein 78/94; GYS1, glycogen synthase 1; hAAT, human AAT; HCC, hepatocellular carcinoma; hMSCs, human BM-derived mesenchymal stem cells; HNF4a, hepatocyte nuclear factor 4 alpha; HPCs, hepatic progenitor cells; IHC, immunohistochemistry; iPS, induced pluripotent stem; NOD-SCID, nonobese diabetes/severe combined immunodeficient; PAS, periodic acid Schiff's; PH, partial hepatectomy; Pkrdc, protein kinase, DNA-activated, catalytic polypeptide; a-SMA, alpha-smooth muscle actin; TAT, tyrosine aminotransferase; TUNEL, terminal deoxynucleotidyl transferase-mediated nick-end labeling; UPRs, unfolded protein responses; WT, wild type.
hepatocytes to form globules. As globules are retained, ER stress causes injury to hepatocytes. Furthermore, low levels of serum AAT (<15% of the normal) may lead to early onset of emphysema. (3) Thus, AAT deficiency (AATD) may be responsible for serious lung disease in adults and/or liver disease in all age groups of patients. (4) Genetic epidemiological surveys in 58 countries indicated that there are approximately 3.4 million individuals with mutant allele combinations (PiSS, PiSZ, and PiZZ). (5) Augmentation therapy with purified AAT from serum or recombinant AAT increases the level, thereby slowing down or preventing progression of emphysema. However, this lifelong treatment is not an affordable option for many patients. Moreover, the augmentation therapy cures emphysema, but not liver-related complications. (6) Attempts have been made in the past 10 years to treat patients either by improving the secretion of mutated AAT protein or by inhibiting neutrophil elastase activity. However, the results were not encouraging attributable to poor therapeutic outcome and toxic side effects. (7) (8) (9) In the mouse, a gene therapy approach using lentiviral-transduced AAT gene in hepatic stellate cells was found to be promising, (10) but it may be noted that such treatment did not influence the pathogenesis of the disease. An alternative to gene therapy, antisense oligonucleotide treatment, when administered early therapy to young animals, stopped disease liver progression, whereas reversal of disease and reduction of fibrosis were observed in the mouse only after long-term treatment. (11) However, marked reduction of circulating AAT in nonhuman primates (11) may lead to lung-associated problems.
Transplantation of primary hepatocytes offered several advantages, given that it replaced major mutated host hepatocytes as shown by near complete reduction of periodic acid Schiff's (PAS)-stained globules and resolved liver fibrosis in the mouse. (12) It remains to be shown whether engrafted hepatocytes can synthesize and secrete native AAT to neutralize neutrophil elastase activity. Paradoxically, acute shortage of donor livers is the main obstacle for success in hepatocyte transplantation. For the first time, gene editing for correction of AATD through induced pluripotent stem (iPS) cells has been reported in the mouse. (13) Using zinc finger nucleases and piggyBac transposons, it was shown that genetic correction of the disease would possibly be more efficiently than the other genetargeting approaches. (13) More recently, iPS cellderived hepatocytes were used for regeneration of AATD mouse liver and hence treatment of the disease. The iPS cell-based treatments have great potential in the future, but safety and economic feasibility of the technology are two major issues that need to be addressed.
Earlier studies have shown that bone marrow (BM) cell therapy leads to the correction of hereditary tyrosinemia type I in the Fah -/-mouse. (14, 15) It was shown that such genetic correction occurs through partial nuclear reprogramming in heterotypic fused cells. In the past, we have shown bleeding phenotype correction in hemophilia A mouse by transplanting BM-derived cells. (16, 17) In this model, expression of factor VIII protein by donor-derived cells can be explained by activation of factor VIII gene after partial nuclear reprogramming of cells. In the present investigation, we wanted to know whether BM-derived cells are able to replace PAS-stained globule-containing hepatocytes, resolve liver fibrosis, and correct dysfunctional glycogen storage in a transgenic mouse model that expresses mutant human AAT. Preliminary results showed that globule-free hepatocytes can proliferate in response to regenerating cues in PiZ mouse liver and render partial improvement of liver glycogen storage and pathology. It was also found that human BMderived mesenchymal stem cells (hMSCs) were able to reduce the accumulation of diastase resistant PASstained globules in severe combined immunodeficient (SCID)-PiZ mouse liver.
Materials and Methods

MICE
Eight-to 10-week-old homozygous PiZ (expressing transgenic hAATZ) mice on a C57Bl/6J background (18) and enhanced green fluorescence protein (eGFP)-expressing [C57Bl6/J-Tg (UBCGFP) 30Scha/J] mice were used in this study. We also used Beige/J mice (Lyst bg ) and in-house developed doublemutant SCID-PiZ mice for transplantation of hMSCs. PiZ mice were donated by St. Louis University (St. Louis, MO); eGFP and nonobese diabetes/ severe combined immunodeficient (NOD-SCID) mice were procured from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were kept in individual ventilated cages and fed with autoclaved acidified water and irradiated food ad libitum. All experiments were conducted as per procedures approved by the Institutional Animal Ethics Committee at National Institute of Immunology, New Delhi.
EXPERIMENTAL PLAN AND TRANSPLANTATION
Three groups consisting of a total of 36 male PiZ mice were transplanted (PiZ-Tx) with Lin -BM cells (0.5 3 10 6 cells in 50 lL of normal saline/mouse) of female eGFP transgenic mice through the intrasplenic route. Mice were euthanized to investigate liver pathology, engrafting ability and phenotype of the donor cells, liver function, etc. Age-matched mice were given normal saline injection and considered as sham control (PiZ-control). Ten-week-old SCID-PiZ (n 5 10) and acetaminophen-induced acute liver injured Beige/J (n 5 6) mice were transplanted with hMSCs (0.5 3 10 6 cells in 50 lL of normal saline/mouse) of passage 5 through the same route. Sham control mice (n 5 3) received normal saline. These mice were euthanized for the analysis of engrafting ability, genes, and protein expression.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
Five-micron sections of formalin-fixed, paraffinembedded liver tissue were used to examine inflammatory reactions, fibrosis, and content of PiZ globules. Details of the staining procedures are given in the Supporting Methods. Similarly, 5 lm of fixed frozen liver tissue sections were used for immunohistochemistry (IHC) analyses. Sections were treated with 0.15% Triton X-100, washed, and stained with primary antibodies for 1 hour. After washing three times, tissue sections were stained with secondary antibody-conjugated fluorochromes for 1 hour. The sections were further washed, and the nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Sections were imaged with a DP70 digital camera equipped with an IX51 Olympus fluorescence microscope (Olympus, Tokyo) using LCPlanFl 203 and 603 objectives through Image Pro Express software (Media Cybernetics Inc., Rockville, MD). Images were also captured using a Leica SP5 II confocal laser-scanning microscope (Leica Biosystems, Nussloch, Germany) with Plan-Apochromat 633/1.4 oil objective and LAS/AF Lite software for analysis. Images were composed and edited in Photoshop 6.0 (Adobe). Details of antibodies used in this study are provided in Supporting Table S1 .
PARTIAL HEPATECTOMY
6 or 12 months following transplantation, mice were subjected to partial hepatectomy (PH; 70%). A few mice received intraperitoneal injection of bromodeoxyuridine (BrdU; 2 mg/mice) and were fed with BrdUsupplemented (1 mg/mL) water. 3 or 15 days following PH, mice were sacrificed. Paraffin-embedded liver sections were costained with Ki67 or BrdU with eGFP or human AAT (hAAT) antibodies to compare the proliferation status of hepatocytes.
GENE SEQUENCING
Genomic DNA (gDNA) was isolated from normal human cells as well as PiZ-control and PiZ-Tx (GFP 1 /GFP -) cells using TRIZOL Reagent (Invitrogen, Carlsbad, CA), following the manufacturer's instructions. DNA samples were amplified using Platinum PCR SuperMix (catalog no.: 12532-016; Invitrogen) and specific primers (SigmaAldrich). The primer sequences were: forward (GTGACAGGGAGGGAGAGGAT) and reverse (GACAAGGAAGACTGGAGCCC).
Amplified DNA samples were resolved on 1% agarose gel and extracted using the Thermo Scientific GeneJET Gel extraction Kit (catalog no.: K0691). Finally, purified samples were sequenced using an ABI 3130 genetic analyzer (Applied Biosystems) (DNA Sequencing facility, UDSC, New Delhi, India).
SUPPORTING METHODS
Other methods, including development of SCIDPiZ mouse, liver perfusion and isolation of hepatocytes, isolation and characterization of donor cells, enzyme-linked immunosorbent assay (ELISA), western blottings, terminal deoxynucleotidyl transferasemediated nick-end labeling (TUNEL), fluorescent in situ hybridization (FISH) assays, liver function tests, glycogen and glucose estimation, hydroxylproline assay, RT-PCR, and primer design (Supporting Table  S2 ), etc., are described in the Supporting Methods.
STATISTICAL ANALYSIS
Results of multiple experiments/samples are reported as mean 6 SEM. The Student t test was carried out to calculate the significance between the means of two groups, and P < 0.05 was considered as significant. All analyses were carried out using GraphPad Prism software.
Results
AATZ GLOBULE-CONTAINING HEPATOCYTES WERE PROGRESSIVELY REDUCED IN TRANSPLANTED MICE
The hallmark of PiZ mutation is accumulation of diastase-resistant PAS-stained globules in hepatocytes. To know the effect of Lin -cells (Supporting Fig. S1 ) transplantation on globules loading, mice were sacrificed after 1, 3, and 6 months and liver sections were subjected to PAS staining. Age-matched PiZ-control mice liver sections were taken for comparison. The number of globule-containing hepatocytes was found to decline in the PiZ-Tx group as compared to control mice (Fig. 1A) . Morphometric analysis of the images confirmed that this decline of globule-containing hepatocytes was significant (P < 0.01) in the later two time points; after 6 months of transplantation only, 19.7 6 7.29% of hepatocytes retained PAS-stained globules (Fig. 1A, bar diagram) .
The above results were validated by western blotting analysis (19) of the soluble and insoluble fractions of protein in 6-month liver samples. It was revealed that in reducing gel, both insoluble and soluble fraction of 52 kD of hAATZ protein was significantly reduced in PiZ-Tx, as compared to PiZ-control liver (Fig. 1B) . Overall, these experiments provide evidence that transplantation of Lin -cells results in a decrease of globular hAATZ protein.
TRANSPLANTATION OF Lin -CELLS PARTIALLY IMPROVES LIVER PATHOLOGY
Quantitative analyses of the pathological changes of liver were based on inflammation (combination of lobular, perivenous, and portal), fibrosis, ER stress, and cellular apoptosis. There was a significant increase of inflammatory reactions in PiZ mice when compared to healthy control C57Bl6/J mice. Six months posttransplantation, inflammation subsided as compared to PiZ-control ( Fig. 2A and Supporting Fig. S2 ). Furthermore, recipient mice showed better liver architecture and hepatocytes morphology, which were not observed in PiZ-control mice ( Fig. 2A) . PiZ-control mice, stained with Sirius red, showed progressive liver periportal fibrosis that was arrested and substantially regressed after transplantation of cells (Fig. 2B ). Hepatic collagen content was estimated by image analysis of Sirius red-stained collagen. The collagen proportionate area (CPA) gradually increased to 5.58 6 0.69% in PiZ-control mice within 6 months (Fig. 2B , bar diagram). Interestingly, hepatic collagen content did not increase significantly, but rather declined to 3.18 6 0.29% in transplanted mice. This decrease of collagen content in PiZ-Tx mice was validated by hydroxyproline assay, in which a similar trend was observed (Fig. 2C ). To support the antifibrotic effect of Lin -cells, we determined the residual activated hepatic stellate cells (aHpSCs) number in terms of alpha-smooth muscle actin (a-SMA) area. The results indicated a significant (P < 0.01) decline of aHpSCs in PiZ-Tx when compared to the PiZ-control group by 6 months posttransplantation ( Fig. 2D and Supporting Fig. S3 ).
Sera alanine aminotransferase, bilirubin, and albumin levels in healthy, PiZ-control, and PiZ-Tx mice were found to be comparable (Supporting Fig. S4 ). These results suggest that though liver pathology was severely affected in PiZ mice, its functions were not compromised.
Accumulation of hAATZ protein in hepatocytes may lead to ER stress, resulting in apoptotic cell death. We analyzed the expression of a few stress-response genes in PiZ and PiZ-Tx mice. Quantitative RT-PCR results showed that C/-EBP homologous protein (CHOP) was up-regulated by 2.6-fold in PiZ-control mice, which was significantly reduced in transplanted mice (Fig. 2E) . Similarly, other stress signals, such as glucose-regulated proteins 78 and 94 (GRP78 and GRP94), growth arrest and DNA-damage inducible protein (GADD34), and activating transcription factor 4 (ATF4), also declined in transplanted liver as compared to PiZ-control mice (Fig. 2E) . We also compared TUNEL-positive hepatocytes in PiZ-control and PiZ-Tx mice. Cellular apoptosis declined in the later group ( Fig. 2F and Supporting Fig. S5 ). Other than hepatocytes, many nonparenchymal cells also were protected from apoptosis in PiZ-Tx mice. These analyses support the notion that transplantation results in partial improvement of liver pathology. 
LIVER GLYCOGEN AND SERA GLUCOSE LEVELS ARE IMPROVED IN PiZ-Tx MICE
In PiZ mice, liver glycogen level declined. Therefore, we investigated whether transplantation results in partial restoration of glycogen storage in liver. PiZcontrol mice demonstrated a 66% drop in glycogen level compared to wild-type (WT) mice (Fig. 3A) . Given that PiZ mice were 20% lighter than WT, the corrected glycogen levels in PiZ-control mice was 69.0 6 16.50 lg/mg of tissues, which improved to 118.6 6 31.37 lg/mg of tissue posttransplantation (Fig. 3A) .
Given that hepatic glycogen maintains serum glucose level, we were also interested to know the effect of transplantation on its level. After incorporating body weight corrections, sera glucose levels in PiZ-control mice were 80.9 6 34.43 mg/dl, which significantly (P < 0.01) elevated to 126.9 6 38.87 mg/dL in PiZ-Tx mice (Fig. 3B ). The results above clearly indicate that PiZ-control mice are inherently hypoglycaemic attributable to low hepatic glycogen storage. Transplantation of Lin -cells resulted in an increase of glycogen storage attributed to the healthy metabolic activity of the livers, leading to improvement of sera glucose levels.
DONOR-DERIVED CELLS EXPRESS ALBUMIN, PROLIFERATE AND RETAIN XX CHROMOSOME
To examine the engraftment of donor cells, liver sections of recipient mice were costained with eGFP and hAAT antibodies. Confocal microscopy results show that eGFP-expressing cells replaced globulecontaining hepatocytes (Fig. 4A) . Even host hepatocytes were replaced. A background expression of hAAT was noticed in eGFP-expressing cells, which may be the soluble form of protein, the gene of which was acquired from host hepatocytes. As eGFPexpressing cells assumed hepatic morphology, liver sections were costained with antimouse albumin (Alb) and eGFP antibodies. The representative photomicrographs suggested that these cells are hepatocyte-like cells, given that most of them expressed Alb (Fig. 4A,  lower panel) . Morphometric analysis of the images (Supporting Fig. S6, 2003) showed that Alb-and eGFP coexpressing cells got progressively increased up to 39.45 6 4.0% of total hepatocytes in a period of 6 months posttransplantation (Fig. 4B) .
The results indicated that eGFP-expressing hepatocytes were competitively selected over host hepatocytes to accomplish homeostasis in liver. To validate proliferation potential of these cells in response to tissue damage, we performed 70% PH 6 and 12 months posttransplantation. After 3 and 15 days of PH, liver sections were costained with either eGFP-Ki67 (6 months) or eGFP-BrdU (12 months ) cell numbers, respectively. The results showed that in the 6-month group, proliferation of eGFP-expressing hepatocytes was more (26.37 6 3.37% vs. 7.53 6 1.96%) than of host hepatocytes (Fig. 4C) . In the 12-month group, eGFP-expressing hepatocytes (eGFP splitting of heterokaryons formed by fusion of BM cells and hepatocytes. (20) To investigate the ploidy status of eGFP-expressing hepatocytes, we analyzed sorted cells (purity, >96%; Supporting Fig. S8) 6 months posttransplantation in a sex-mismatched model by interphase X, Y FISH. The photomicrograph (Fig. 4D, left) shows a distinct nuclei of donor (XX) and recipient (XY) cells in a mixture of two types of cells. The sorted cells showed mostly donor-derived (XX) with a few heteroploid (XXXY) cells (Fig. 4D,  right) . Furthermore, cytogenetic analyses of 1,015 nuclei of 3 mice suggest that 4.18% of the total cells consisted of heteroploid (XXXY) nuclei and discrete 2X, 4X, and 6X cells comprised 79.41%, 2.9%, and 2.27%, of the cells, respectively (Fig. 4D, Table) .
TRANSPLANTATION RESULTS IN IMPROVED PROLIFERATION OF GLOBULE-DEVOID RATHER THAN GLOBULE-CONTAINING HEPATOCYTES
Earlier, it was shown that due to ER stress, globulecontaining hepatocytes proliferate more slowly than globule-devoid hepatocytes. (21) In order to determine the effect of transplantation on proliferation of globule-devoid versus globule-containing hepatocytes, liver sections of PiZ-control (without PH), PiZcontrol (with PH), and PiZ-Tx (with PH) mice were stained with hAAT and Ki67 antibodies. In these three groups, percentage of Ki67 
Globule
1 and Ki67 1 Globule -hepatocytes were counted and compared. Interestingly, PiZ-Tx mice exhibited lower mortality (20%) than PiZ-control mice (50%) post-PH; this could be attributed to the proliferation restriction of globule-containing hepatocytes as a result of ER stress. Quantitative analysis revealed that in all three groups, globule-devoid hepatocytes had undergone significantly (P < 0.05-0.01) higher proliferation than globule-containing hepatocytes (Fig. 5A) . The maximum proliferation was noticed in PiZ-Tx (PH) when compared to the other two groups (15.0 6 1.14% vs. 8.26 6 0.54% vs. 6.61 6 2.75%). These results support our earlier observations (Fig. 1A) and explain the reason why the number of PAS 1 hepatocytes was reduced posttransplantation.
It is possible that in PiZ mice, hepatic progenitor cells (HPCs) are the primary contributors in liver regeneration. Given that hyperproliferation of HPCs increases the risk of hepatocellular carcinoma (HCC), we also examined for any effect of transplantation on field) in PiZ-control mice, indicating more ductular reactions (Fig. 5B, right image) . Interestingly, the number of HPCs declined after transplantation of cells, suggesting that ductular reactions were reduced (Fig. 5B, bottom image) . Furthermore, to ensure that transplantation did not increase the risk of HCC, we conducted pathological examination of liver sections to identify any nodular lesion, abnormal cell density, formation of neovasculatures, etc., if any. The results indicated no adverse changes in the PiZ-Tx mice group as compared to PiZ-control mice (Supporting Fig. S9 ).
EXPRESSION OF HUMAN AAT GENE AND PROTEIN IN eGFP-EXPRESSING HEPATOCYTES
Our earlier experiment pointed toward expression of human AAT protein in eGFP-expressing hepatocytes (Fig. 4A, middle panel) . Given that these cells are not supposed to express human AAT protein, we hypothesized that the human gene was transferred to the donor cells' genome as a result of nuclear fusion between two cellular partners. Subsequent analysis of tissue sections showed that the globular form of the human AATZ protein was also present in a few eGFP-expressing cells (Fig. 6A, left image) . The inset distinctly shows one of the hepatocytes in the eGFP-sorted cells from transplanted mice containing PAS-stained globules. On average, 10.5 6 2.5% of BM-derived cells were found to possess PAS-stained globules. The image at low magnification (2003) shows more globules in the cells (Fig. 6A, right image) .
To confirm that eGFP-expressing hepatocytes received human AAT gene through nuclear fusion, we conducted PCR-based analysis of both the mouse and human AAT gene. The results show that the WT mouse did not express the human gene, whereas PiZcontrol and eGFP-sorted hepatocytes from transplanted mice confirmed the presence of human AAT gene of 960 base pairs (bp; Fig. 6B ). Thus, we conclude the gain of human AAT gene by eGFPexpressing hepatocytes.
It is apparent that human AAT gene is present in recipient and eGFP-expressing hepatocytes of transplanted mice. Given that only 25% hepatocytes contain PAS-stained globules (Fig. 1A) , it is quite likely that in the remaining cells, hAAT was expressed in soluble forms (monomer AATZ and/or native AAT). Given that WT AAT gene can only synthesize native protein, we investigated whether partial nuclear reprogramming leads to gene correction. The qualitative analysis of hAAT gene by DNA sequencing revealed that mutation was still present in donor-derived cells, where "G" was replaced with "A" (Fig. 6C) .
HUMAN BM-MSCs TRANSPLANTATION LEADS TO REDUCTION OF AATZ GLOBULE-CONTAINING HEPATOCYTES
To know whether the recipient liver also responds in a reproducible manner in the case of human cells, we first created SCID-PiZ chimera by crossing the NOD-SCID and Bl6/J-PiZ mouse. The homozygous double-mutant mice were characterized by genotyping for AATZ and SCID (protein kinase, DNA-activated, catalytic polypeptide; Pkrdc) genes and by ELISA for human AAT protein in sera. The representative results of 1 such male mouse (M1) indicated the presence of both Pkrdc and AATZ genes (Fig. 7A) . The ELISA results of three pairs of PiZ and SCID-PiZ mice showed that circulating sera protein levels were reduced by 70% of the normal level, further confirming the generation of human PiZ mutant on the SCID background (Fig. 7B) .
The PAS-stained liver sections ensured the presence of AATZ globules in hepatocytes of SCID-PiZ mice (Fig. 7C, middle) . Transplantation of 0.5 3 10 6 hMSCs (Supporting Fig. S10 ) resulted in reduction of PAS-stained globules to 25.52 6 6.22% within 3 months (Fig. 7C, bar diagram) . As in previous experiments, the fate of hMSCs in the liver milieu was examined by staining for human Alb alone and for CK18. The results confirmed a phenotype change of engrafted cells in favor of hepatocytes (Fig. 7D, i , ii, bar diagram). Morphometric analysis suggested that 13.4 6 1.2% hepatocytes were potentially donor-cells derived. A small fraction (3.33 6 0.67%) of donorderived cells also contained AATZ globules (Fig. 7D,  iii, bar diagram) . Further analysis revealed that these cells coexpressed Alb and CK 18 (Fig. 7D, iv-vi) . Gene expression analysis showed that besides human hepatocyte nuclear factor 4 alpha (HNF4a) and albumin, many functional genes like tyrosine aminotransferase (TAT), cytochrome P450 2B6 (CYP2B6), and glycogen synthase 1 (GYS1) were also expressed in SCID-PiZ mouse livers 3 months posttransplantation (Fig. 7E) .
Given that AAT protein is typically produced by hepatocytes, we examined its expression by donorderived cells. To avoid intense background staining of the globular protein in SCID-PiZ mouse, we used the Beige/J mouse (Lyst bg ) as recipient, which has impaired natural killer cell function. The results clearly demonstrated that hMSC-derived cells expressed AAT protein (Fig. 8A) , which was secreted in the circulation (Fig. 8B) . Overall, these preliminary experiments suggested that hMSCs are capable of converting into hepatocyte-like cells that express AAT, causing partial reduction of AATZ globules.
Discussion
In cases of AATD, the likelihood of effects in both lung and liver are high. The ideal therapeutic strategy should be to prevent both pulmonary emphysema and liver disease. Unfortunately, current treatments aim at pulmonary emphysema. There is no clinically established treatment available that can cure AATD-associated liver disease alone or with emphysema. Severe cases of AATD can be managed by orthotopic liver transplantation or transferring primary hepatocytes. (12) However, the success has been limited because of an inadequate supply of tissue-matched cadaver organs. The advancement of stem cells and molecular biology techniques has allowed investigators to explore better treatment options in many liver diseases. This could be done by replacing mutated hepatocytes with healthy iPS/embryonic stem-derived hepatocytes, or editing mutated gene(s) in a patient's own cells. (13) It is needless to mention that iPS cell-based treatments will take longer before being used clinically. In this study, we have shown a potential application of BM-derived stem cells that are easily obtained in large quantities and are being used in many clinical trials. The main advantage of mesenchymal stem cells (MSCs) is that they can be harvested from Wharton jelly or adipose tissue as opposed to BM and are hypoimmunogeneic. In this study, BM-derived cells did not completely improve liver pathology and replaced globules containing hepatocytes as observed in the case of primary hepatocytes. (12) This may be attributed to the low number of cells being used in transplantation. Given that transplantation of human hepatocytes is not a feasible treatment for cellular therapy, BM-derived cells may prove beneficial in the future.
The benchmark of pathological improvement was gradual loss of PAS-stained globules of AATZ protein in transplanted mouse liver. Here, we proposed a relationship between percentage donor-cells' chimera and replacement of globules-containing hepatocytes. The increase of eGFP-expressing hepatocytes for 6 months posttransplantation was possibly attributed to impaired proliferation responses of globule-containing host cells. We also observed comparative proliferative response in globule-devoid hepatocytes in PiZ-control (PH) and PiZ mice, despite an expected high regeneration signal in the former group. On the other hand, proliferative responses of globule-devoid hepatocytes in PiZ-Tx (PH) mice were significantly higher than PiZ-control (PH) mice. The observation that AATZ globulebearing hepatocytes proliferate much less than globuledevoid cells is consistent with the earlier literature. (21) This was probably attributable to proliferative disadvantage and apoptotic death of globule-bearing hepatocyt. (22) Relatively high expression of CHOP and more TUNEL-positive cells confirmed apoptotic death of hepatocytes in PiZ mice attributable to persistent ER stress. ER stress signal results in activation of unfolded protein responses (UPRs). Cells regulate this by overexpressing ER chaperones and degradation factors in order to minimize the accumulation of misfolded proteins and hence ER stress. (22) Expression of many such stress-relieving factors is regulated by ATF3/4/6, members of the bZIP family of transcription factors. (23) ATF4-mRNA is constitutively expressed in many cells; however, its expression and protein translation are induced under stress, (23, 24) which corroborate our gene expression results. Though we did not study the activation of ATFs, it is possible that UPR led to their activation resulting in induction of CHOP, GRP78, GRP94, and GADD34 expression. (23) Interestingly, stress signals and cellular apoptosis considerably declined in PiZ-Tx mice, probably attributed to cellular homeostasis. It may be possible that GADD34-mediated dephosphorylation of eukaryotic initiation factor 2a inhibited stressinduced gene expression for the recovery from translational inhibition in UPR. (25) The decline of ER stress could also be attributed to low numbers of globulecontaining hepatocytes.
Though globule-devoid hepatocytes preferentially proliferated, our results were not consistent with the selective proliferative advantage model (26) given that globule-containing hepatocytes were not reduced in control PiZ mice upon aging. The decrease in PAS 1 hepatocytes in SCID-PiZ mouse using hMSCs further supported the beneficial effect of transplantation and revealed that the pathological improvement of liver is also applicable in xenograft models.
Chronic liver injury was found to be associated with proliferation of HPCs (increased ductular reactions). HPC proliferation increases the risk of dysplastic regenerative nodules in liver and HCC in human ZZ mutant and PiZ mouse. (27) Low ductular reaction in PiZ-Tx, as compared to PiZ-control mice, suggested HCC was not augmented, if not reduced, because of transplantation. (28) Besides intracellular globules, slow progression of fibrosis with low-grade inflammation, mild steatosis, etc., has been reported in PiZ mice. (29, 30) An earlier study has classified inflammation in PiZ mice in three categories: portal, perivenous, and lobular. Interestingly, significant declines in inflammatory responses were observed in transplant recipients. The reason, though not clearly understood, may be attributed to increase of autophagy, which might have prevented cell death and subsequent infiltration of immune cells. (27) It was shown that autophagy involves maintenance of homeostasis and cell growth in PiZ mice by degradation of insoluble AATZ globules. (27, 31) Another beneficial effect of BM cell therapy was partial resolution of periportal fibrosis, which was shown as a characteristic pathological feature of AATD mice. (32) Earlier reports demonstrated a dramatic reduction of collagen deposition in AATD mice by transplanting primary hepatocytes (12) or antisense oliogonucleotide targeting the hAAT gene. (11) Low regression of fibrosis in this case, when compared with previous reports, (11, 12) was probably attributed to lack of the fibrolytic enzyme, matrix metalloproteinase 13, present in the donor cells. (33) Abnormal intracellular protein conformation in the PiZ mouse may lead to metabolic shifts in the liver, which reduces liver glycogen storage, lowers serum glucose level, and decreases body weight, etc. (34) Partial recovery in liver glycogen and sera glucose levels in PiZ-Tx mice exhibited the improvement from the gain-of-toxic function associated with AATD. These results, together with relatively higher proliferation of hepatocytes, explained why mortality rate in PiZ-Tx mice post-PH was considerably reduced as compared to PiZ-control mice.
The increasing trend of donor cells' contribution in recipient mice was probably attributed to two possible reasons: (1) intrasplenic transplantation allowed better engraftment of cells given that they entered through the portal vein to repopulate liver, and (2) high selection pressure for liver regeneration leads to rapid proliferation of globules-devoid eGFP-expressing hepatocytes. We observed traces of donor cells in BM and spleen, but nothing in the kidney and lung (data not shown). Even though BM-derived hepatocytes were reported in the literature, (16, (35) (36) (37) such high numbers have not been shown earlier. Moreover, this lineage conversion has been questioned by many investigators. (14, 15, 38) We propose that heterotypic fused cells had undergone early segregation and maintained respective to the sex chromosomal status of the fusion partners. The host cells did not change the lineage, whereas the donor cells converted into hepatocyte-like cells attributed to partial nuclear reprogramming. Large numbers of eGFPexpressing hepatocytes were attributed to their proliferation. This study could not confirm that the appearance of eGFP-expressing hepatocytes was only from fused cells; this was attributed to the limitation of the present experimental model.
Another new observation made in this study was the presence of hAATZ globules in a few eGFPexpressing hepatocytes. Again, IHC results also indicated a potential soluble form of AAT protein in these cells. Though nuclear reprogramming may lead to transfer of hAAZ gene from host cells chromosome to eGFP-expressing hepatocyets, no gene correction was observed at the DNA level. It is important to note that an earlier publication described correction of mutated fumarylacetoacetate hydrolase gene in type 1 tyrosinemia disease model following cell fusion. (15) Our results conclude that such gene correction may not be possible in the present system. The fact that around 90% of eGFP-expressing hepatocytes did not show globules could be attributed to low-level expression of monomeric AATZ protein in donor-derived hepatocytes. (E) Expression of human-liver-specific genes. SCID-PiZ control liver did not show expressions of human genes, which were highly expressed in the recipient liver within 3 months of transplantation. Number of mice (n) 5 3. **P < 0.01; ***P < 0.001. Abbreviations: DCt, delta threshold cycle; hAlb, human albumin.
In short, we have shown that transplantation of BM cells leads to partial replacement of AATZ globulecontaining hepatocytes, regression of fibrosis, and apparent reduction of apoptosis. This was possibly due to the proliferation of eGFP-expressing hepatocyets over host hepatocytes, which mostly contained PAS Beige/J mice were bled and sera AAT levels were analyzed using a human AAT-specific ELISA kit. The number of mice (n) 5 6. **P < 0.01; ***P <0.001. Abbreviation: hAlb, human albumin.
